WO1992004016A1 - Pharmaceutical composition of florfenicol - Google Patents
Pharmaceutical composition of florfenicolInfo
- Publication number
- WO1992004016A1 WO1992004016A1 PCT/US1991/005899 US9105899W WO9204016A1 WO 1992004016 A1 WO1992004016 A1 WO 1992004016A1 US 9105899 W US9105899 W US 9105899W WO 9204016 A1 WO9204016 A1 WO 9204016A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- florfenicol
- pyrrolidone
- pharmaceutical composition
- weight
- polyethylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- This invention relates to pharmaceutical compositions containing florfenicol as the active ingredient, and particularly to injectable compositions having a high concentration of florfenicol.
- Florfenicol [D-(threo)-1-p-methylsulfonyl phenyl-2-dichloroacetamido-3-fluoro-1-propanol] is a known antibacterial agent and is useful for veterinary purposes. When treating a large animal, it is sometimes desirable to administer a composition having a high concentration of florfenicol. The large amount of florfenicol thus administered should then preferably exhibit constant blood levels and be active for a prolonged period of time.
- Florfenicol has low solubility in water, about 1.3 mg/ml, and the preparation of a concentrated aqueous injectable solution is not practicable due to the large volume required to administer a therapeutic dose.
- Florfenicol also exhibits low solubility in many pharmaceutically acceptable organic solvents such as 1,2-propanediol, glycerin, and benzyl alcohol.
- Florfenicol is generally soluble in aprotic polar solvents, such as N-methyl-2-pyrrolidone or 2- pyrrolidone; however, concentration of these solvents at levels greater than 30% was found to cause injection site irritation and tissue damage upon intramuscular administration.
- aprotic polar solvents such as N-methyl-2-pyrrolidone or 2- pyrrolidone
- the novel compositions provide constant blood levels over a prolonged period of time and exhibit excellent physical and chemical stability.
- FIGURE 1 illustrates serum florfenicol levels in calves after single intramuscular 20 mg/kg dose.
- Florfenicol exhibits antibacterial activity and is useful in veterinary medicine (Merck Index, 11th Edition, No. 4042).
- U.S. Patent No. 4,235,892 describes the compound and processes for making said compound; this patent is incorporated herein by reference.
- a novel composition has been prepared which provides relatively high concentrations of florfenicol in a unique organic solvent system of a pyrrolidone solvent such as 2- pyrrolidone, N-methy1-2-pyrrolidone; polyethylene glycol, and a viscosity reducing agent.
- a pyrrolidone solvent such as 2- pyrrolidone, N-methy1-2-pyrrolidone
- polyethylene glycol such as polyethylene glycol
- a viscosity reducing agent such as 2- pyrrolidone, N-methy1-2-pyrrolidone
- compositions according to the present invention may comprise from 10 to 50% by weight of florfenicol, and preferably from 20 to 40% by weight.
- the pyrrolidione solvents that can be utilized in this invention include 2-pyrrolidone and N-methyl-2- pyrrolidone.
- the preferred solvent is N-methy1-2- pyrrolidone.
- the amount of pyrrolidone solvent in the compositions of the present invention may comprise from 10 to 65% by weight of the total composition. Compositions containing above 30% by weight N-methyl-2- pyrrolidone solvent may cause injection site irritation and tissue damage upon intramuscular injection in cattle.
- the polyethylene glycols which are used in the compositions of the present invention include those having an average molecular weight of from 200-400.
- the preferred polyethylene glycol has an average molecular weight of about 300 and is also referred to as PEG 300.
- the amount of polyethylene glycol present in the compositions of the present invention is from 5 to 45% by weight, and preferably from 30 to 40% by weight.
- a viscosity reducing agent is required to provide a product with workable syringeability.
- examples of viscosity reducing agents useful in the present invention include: ethanol and propylene glycol.
- the preferred viscosity reducing agent is propylene glycol.
- the amourt of viscosity reducing agent employed in the compositions of the present invention is from 5 to 15% by weight of the composition; preferably 10 to 15% by weight.
- compositions of the present invention are readily prepared by mixing the pyrrolidone solvent and the viscosity reducing agent with approximately 90% of the polyethylene glycol component.
- the florfenicol is dissolved in the solution and the volume is adjusted with the remaining polyethylene glycol.
- the resulting clear solution is sterilized by filtration.
- compositions of the present invention exhibit desirable properties which are useful for administration of relatively high concentrations of florfenicol.
- the compositions have desirable viscosity characteristics which allows for good syringeability over a wide temperature range and ease of processing, such as good flow rate through sterilizing filter membranes.
- the compositions are physically and chemically stable, for example, the compositions are stable and maintain specification for at least two years when stored at temperatures between 2°C and 30°C.
- the compositions provide therapeutic blood levels over a prolonged period of time and also exhibit acceptable tissue toleration.
- EXAMPLE 1 An injectable solution is prepared from the following:
- the solution is prepared according to the following procedure: The N-methyl-2-pyrrolidone, propylene glycol and approximately 90% of the polyethylene glycol 300 required are mixed well and then florfeniclol dissolved in the mix. The volume is adjusted with the PEG 300 remaining and the clear solution is sterilized by filtration.
- EXAMPLE 2 An injectable solution is prepared from the following:
- the solution is prepared according to the following procedure: The N-methyl-2-pyrrolidone, ethanol and approximately 90% of the polyethylene glycol 300 required, are mixed well and then florfenicol dissolved in the mix. The volume is adjusted with the PEG 300 remaining and the clear solution is sterilzed by filtration.
- EXAMPLE 3 An injectable solution is prepared from the following:
- EXAMPLE 4 An injectable solution is prepared from the following:
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69104724T DE69104724T2 (en) | 1990-08-29 | 1991-08-27 | FLORFENICOL CONTAINING MEDICINAL PRODUCT. |
SK129-93A SK279290B6 (en) | 1990-08-29 | 1991-08-27 | Pharmaceutical composition for veterinary use |
UA93080804A UA27244C2 (en) | 1990-08-29 | 1991-08-27 | Liquid antibacterial composition |
AU84366/91A AU655935B2 (en) | 1990-08-29 | 1991-08-27 | Pharmaceutical composition of florfenicol |
PL91298148A PL171466B1 (en) | 1990-08-29 | 1991-08-27 | Method of obtaining a pharmaceutic agent for use in veterinary medicine |
KR1019930700553A KR960005705B1 (en) | 1990-08-29 | 1991-08-27 | Pharmaceutical composition of florfenicol |
JP3514851A JPH0692299B2 (en) | 1990-08-29 | 1991-08-27 | Florfenicol pharmaceutical composition |
RU9193005176A RU2085191C1 (en) | 1990-08-29 | 1991-08-27 | Liquid antibacterial composition |
CZ93257A CZ280541B6 (en) | 1990-08-29 | 1991-08-27 | Pharmaceutical mixtures of phlorphenicol |
EP91915522A EP0546018B1 (en) | 1990-08-29 | 1991-08-27 | Pharmaceutical composition of florfenicol |
NO930616A NO301746B1 (en) | 1990-08-29 | 1993-02-22 | Process for the preparation of a pharmaceutical preparation for veterinary use of florfenicol |
FI930844A FI101596B (en) | 1990-08-29 | 1993-02-25 | The method produces a stable injectable pharmaceutical composition of florfenicol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/574,430 US5082863A (en) | 1990-08-29 | 1990-08-29 | Pharmaceutical composition of florfenicol |
US574,430 | 1990-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992004016A1 true WO1992004016A1 (en) | 1992-03-19 |
Family
ID=24296100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/005899 WO1992004016A1 (en) | 1990-08-29 | 1991-08-27 | Pharmaceutical composition of florfenicol |
Country Status (29)
Country | Link |
---|---|
US (1) | US5082863A (en) |
EP (1) | EP0546018B1 (en) |
JP (1) | JPH0692299B2 (en) |
KR (1) | KR960005705B1 (en) |
CN (1) | CN1041793C (en) |
AT (1) | ATE112959T1 (en) |
AU (1) | AU655935B2 (en) |
CA (1) | CA2090422C (en) |
CZ (1) | CZ280541B6 (en) |
DE (1) | DE69104724T2 (en) |
DK (1) | DK0546018T3 (en) |
ES (1) | ES2065059T3 (en) |
FI (1) | FI101596B (en) |
HK (1) | HK185896A (en) |
HU (1) | HU213406B (en) |
IE (1) | IE66925B1 (en) |
IL (1) | IL99337A (en) |
MX (1) | MX9100855A (en) |
MY (1) | MY106780A (en) |
NO (1) | NO301746B1 (en) |
NZ (1) | NZ239559A (en) |
PL (1) | PL171466B1 (en) |
PT (1) | PT98790B (en) |
RU (1) | RU2085191C1 (en) |
SK (1) | SK279290B6 (en) |
TW (1) | TW215054B (en) |
UA (1) | UA27244C2 (en) |
WO (1) | WO1992004016A1 (en) |
ZA (1) | ZA916780B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014340A1 (en) * | 2002-08-13 | 2004-02-19 | Dae Han New Pharm Co., Ltd. | Injectable composition comprising florfenicol as an active ingredient |
KR20040015624A (en) * | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | Oral injectable pharmaceutical composition comprising florfenicol as active ingredient |
KR20040020086A (en) * | 2002-08-29 | 2004-03-09 | 주식회사 성원 | Composition for Preventing and Treating Respiratory Disease of Livestock Animal |
AU2004262501B2 (en) * | 2003-07-31 | 2008-11-20 | Calluna Pharma Bvba | Veterinary aqueous injectable suspensions containing Florfenicol |
EP1345611B1 (en) * | 2000-11-27 | 2010-12-29 | Teva Animal Health, Inc. | An antibiotic/analgesic formulation and a method of making this formulation |
US8314252B2 (en) | 2008-07-30 | 2012-11-20 | Intervet Inc. | Process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol |
US8680154B2 (en) | 2004-12-21 | 2014-03-25 | Intervet International B.V. | Injectable veterinary composition |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1060310C (en) * | 1994-12-04 | 2001-01-10 | 张长兴 | Specific pesticide for control of plant diseases |
CZ293747B6 (en) * | 1995-12-21 | 2004-07-14 | Pfizer Inc. | Aqueous pharmaceutical solution suitable for injection into a host and use thereof |
US5993116A (en) * | 1997-06-30 | 1999-11-30 | Sandvik Rock Tools, Inc. | Filler-containing rock bolt anchoring system and method of preparation thereof |
US6150423A (en) * | 1998-10-15 | 2000-11-21 | Phoenix Scientific, Inc. | Propofol-based anesthetic and method of making same |
US6017948A (en) * | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
US20030068339A1 (en) * | 2001-10-02 | 2003-04-10 | Phoenix Scientific, Inc. | Veterinary florfenicol formulation that is syringeable under cold weather conditions |
GB0205253D0 (en) * | 2002-03-06 | 2002-04-17 | Univ Gent | Immediate release pharmaceutical granule compositions and a continuous process for making them |
AU2003249503A1 (en) * | 2002-03-08 | 2003-09-29 | Schering-Plough, Ltd. | Novel florfenicol-type antibiotics |
US6790867B2 (en) * | 2002-05-20 | 2004-09-14 | Schering-Plough Animal Health Corporation | Compositions and method for treating infection in cattle and swine |
UA82359C2 (en) * | 2003-04-03 | 2008-04-10 | Schering Plough Ltd | Composition (variants) and method for treatment of microbial diseases and parasitic infection in cattle and other animals |
AR044437A1 (en) * | 2003-05-29 | 2005-09-14 | Schering Plough Ltd | COMPOSITIONS AND METHOD FOR TREATMENT OF INFECTIONS IN VACCINE AND PORCINE LIVESTOCK |
US7439268B2 (en) * | 2003-07-18 | 2008-10-21 | Idexx Laboratories | Compositions containing prodrugs of florfenicol and methods of use |
US20050049210A1 (en) * | 2003-08-27 | 2005-03-03 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
US7126005B2 (en) | 2003-10-06 | 2006-10-24 | Aurobindo Pharma Limited | Process for preparing florfenicol |
KR100645268B1 (en) * | 2005-04-04 | 2006-11-14 | 주식회사 고려비엔피 | Pharmaceutical composition for animal drug |
KR100712928B1 (en) * | 2005-08-24 | 2007-05-02 | 엘지전자 주식회사 | Compressure Operate Select Method For Dual Type Unitary Air Conditioner |
US8119667B2 (en) * | 2005-12-29 | 2012-02-21 | Schering-Plough Animal Health Corporation | Carbonates of fenicol antibiotics |
KR100748251B1 (en) * | 2006-05-08 | 2007-08-10 | 주식회사 삼양애니팜 | Composition for injection containing florfenicol |
GB0612695D0 (en) * | 2006-06-27 | 2006-08-09 | Univ Gent | Process for preparing a solid dosage form |
WO2008076259A1 (en) * | 2006-12-13 | 2008-06-26 | Schering-Plough Ltd. | Water-soluble prodrugs of florfenicol and its analogs |
US8044230B2 (en) * | 2006-12-13 | 2011-10-25 | Intervet Inc. | Water-soluble prodrugs of chloramphenicol, thiamphenicol, and analogs thereof |
US7550625B2 (en) * | 2007-10-19 | 2009-06-23 | Idexx Laboratories | Esters of florfenicol |
US20090170954A1 (en) * | 2007-12-14 | 2009-07-02 | Schering-Plough Ltd. | Process for Recovering Florfenicol and Florfenicol Analogs |
BRPI1002021A2 (en) | 2010-01-21 | 2012-05-22 | Nanocore Biotecnologia S A | pharmaceutical compositions for treating bacterial infections |
BRPI1002023A2 (en) | 2010-03-01 | 2011-10-25 | Nanocore Biotecnologia S A | fast dissolving solid dosage form for treating bacterial infections |
CN102973498A (en) * | 2012-12-13 | 2013-03-20 | 江苏恒丰强生物技术有限公司 | Florfenicol injection and preparation method thereof |
EP2995297A1 (en) | 2014-09-09 | 2016-03-16 | Ceva Sante Animale | Parenteral compositions and uses thereof |
KR101642717B1 (en) * | 2015-11-13 | 2016-07-27 | 바이엘코리아주식회사 | Injectable composition containing florfenicol |
CN107582522A (en) * | 2017-11-02 | 2018-01-16 | 山东谊源动物药业有限公司 | A kind of production technology of florfenicol injection |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0014437A2 (en) * | 1979-02-05 | 1980-08-20 | Schering Corporation | Novel 1-aryl-2-acylamido-3-fluoro-1-propanols, their preparation and pharmaceutical compositions containing them |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4423040A (en) * | 1980-04-04 | 1983-12-27 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclohexan-2-ones |
-
1990
- 1990-08-29 US US07/574,430 patent/US5082863A/en not_active Expired - Lifetime
-
1991
- 1991-08-27 AT AT91915522T patent/ATE112959T1/en not_active IP Right Cessation
- 1991-08-27 CA CA002090422A patent/CA2090422C/en not_active Expired - Lifetime
- 1991-08-27 CZ CZ93257A patent/CZ280541B6/en not_active IP Right Cessation
- 1991-08-27 UA UA93080804A patent/UA27244C2/en unknown
- 1991-08-27 SK SK129-93A patent/SK279290B6/en not_active IP Right Cessation
- 1991-08-27 DK DK91915522.6T patent/DK0546018T3/en active
- 1991-08-27 ZA ZA916780A patent/ZA916780B/en unknown
- 1991-08-27 MY MYPI91001559A patent/MY106780A/en unknown
- 1991-08-27 NZ NZ239559A patent/NZ239559A/en not_active IP Right Cessation
- 1991-08-27 EP EP91915522A patent/EP0546018B1/en not_active Expired - Lifetime
- 1991-08-27 HU HU9300555A patent/HU213406B/en active Protection Beyond IP Right Term
- 1991-08-27 DE DE69104724T patent/DE69104724T2/en not_active Expired - Lifetime
- 1991-08-27 RU RU9193005176A patent/RU2085191C1/en active
- 1991-08-27 ES ES91915522T patent/ES2065059T3/en not_active Expired - Lifetime
- 1991-08-27 PL PL91298148A patent/PL171466B1/en unknown
- 1991-08-27 JP JP3514851A patent/JPH0692299B2/en not_active Expired - Lifetime
- 1991-08-27 WO PCT/US1991/005899 patent/WO1992004016A1/en active IP Right Grant
- 1991-08-27 KR KR1019930700553A patent/KR960005705B1/en not_active IP Right Cessation
- 1991-08-27 AU AU84366/91A patent/AU655935B2/en not_active Expired
- 1991-08-28 MX MX9100855A patent/MX9100855A/en unknown
- 1991-08-28 PT PT98790A patent/PT98790B/en not_active IP Right Cessation
- 1991-08-28 CN CN91108502A patent/CN1041793C/en not_active Expired - Lifetime
- 1991-08-28 TW TW080106835A patent/TW215054B/zh not_active IP Right Cessation
- 1991-08-28 IL IL9933791A patent/IL99337A/en not_active IP Right Cessation
- 1991-08-28 IE IE302491A patent/IE66925B1/en not_active IP Right Cessation
-
1993
- 1993-02-22 NO NO930616A patent/NO301746B1/en not_active IP Right Cessation
- 1993-02-25 FI FI930844A patent/FI101596B/en not_active IP Right Cessation
-
1996
- 1996-10-03 HK HK185896A patent/HK185896A/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0014437A2 (en) * | 1979-02-05 | 1980-08-20 | Schering Corporation | Novel 1-aryl-2-acylamido-3-fluoro-1-propanols, their preparation and pharmaceutical compositions containing them |
Non-Patent Citations (1)
Title |
---|
STN International Information Services Data Base: Chemical Abstracts, accession nr. 101 (20):177519f, & JP, A, 59112913 (TAKEDA CHEM. IND. LTD) 29 June 1984, see the abstract * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1345611B1 (en) * | 2000-11-27 | 2010-12-29 | Teva Animal Health, Inc. | An antibiotic/analgesic formulation and a method of making this formulation |
EP2351570A1 (en) * | 2000-11-27 | 2011-08-03 | IVX Animal Health, Inc. | An Antibiotic/Analgesic Formulation And a Method of Making This Formulation |
WO2004014340A1 (en) * | 2002-08-13 | 2004-02-19 | Dae Han New Pharm Co., Ltd. | Injectable composition comprising florfenicol as an active ingredient |
KR20040015624A (en) * | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | Oral injectable pharmaceutical composition comprising florfenicol as active ingredient |
WO2004014341A1 (en) * | 2002-08-13 | 2004-02-19 | Dae Han New Pharm Co., Ltd. | Oral injectable pharmaceutical composition comprising florfenicol as an active ingredient |
KR20040015623A (en) * | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | Injectable Composition Comprising Florfenicol as Active Ingredient |
KR20040020086A (en) * | 2002-08-29 | 2004-03-09 | 주식회사 성원 | Composition for Preventing and Treating Respiratory Disease of Livestock Animal |
AU2004262501B2 (en) * | 2003-07-31 | 2008-11-20 | Calluna Pharma Bvba | Veterinary aqueous injectable suspensions containing Florfenicol |
US8680154B2 (en) | 2004-12-21 | 2014-03-25 | Intervet International B.V. | Injectable veterinary composition |
US8314252B2 (en) | 2008-07-30 | 2012-11-20 | Intervet Inc. | Process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5082863A (en) | Pharmaceutical composition of florfenicol | |
FI78235C (en) | Process for the preparation of a topical anti-inflammatory composite ion in gel ointment form | |
EP1830885B1 (en) | Injectable veterinary composition comprising florfenicol | |
US3265573A (en) | Benzothiadiazinesulfonamide-1, 1-dioxide composition | |
EP0413538A1 (en) | Long active injectable formulations containing triacetin | |
EP0535734A1 (en) | Long acting injectable formulations containing hydrogenated castor oil | |
RU2397753C1 (en) | Composition for treating bacterial infections in animals | |
JPS605567B2 (en) | Oxytetracycline preparation | |
JPS63166832A (en) | Solution for nose | |
RU1836084C (en) | A way of obtaining the preparation for therapy of parasite diseases in animals | |
SK5682000A3 (en) | Compositions containing thiamphenicol and diclofenac | |
EP1129713A1 (en) | Veterinary compositions for the treatment of parasitic diseases | |
KR100586420B1 (en) | Topical composition for treatment of impotence | |
EP0384722A1 (en) | Chemical compositions | |
KR20000033304A (en) | Animal insectifuge composition for injection containing water-soluble polymer and alcohol | |
EP1458389A1 (en) | Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion | |
KR20050103357A (en) | Pharmacological composition containg florfenicol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MC MG MW NO PL RO SD SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991915522 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12993 Country of ref document: SK Ref document number: PV1993-257 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2090422 Country of ref document: CA Ref document number: 930844 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1991915522 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1993-257 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991915522 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1993-257 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 930844 Country of ref document: FI |